ULTRAGENYX PHARMACEUTICAL INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.3M | $363.3M | $351.4M | $271.0M | $103.7M | $91.5M |
| Product Sales Net | — | — | $355.6M | $248.3M | $188.7M | $111.3M | $45.8M | $13.9M |
| Collaboration and License Revenue | — | — | $28.0M | $43.8M | $122.9M | $136.8M | $47.4M | $71.8M |
| Royalty Revenue | — | — | $50.7M | $71.2M | $39.8M | $22.9M | $10.5M | $5.8M |
| Cost of Revenue | — | — | — | — | — | — | — | $1.1M |
| Gross Profit | — | — | — | — | — | — | — | $90.3M |
| Gross Margin | — | — | — | — | — | — | — | 98.7% |
| Operating Expenses | ||||||||
| Research & Development | $750.0M | $698.0M | $648.0M | $705.8M | $497.2M | $412.1M | $357.4M | $294.0M |
| SG&A Expense | $349.0M | $321.0M | $310.0M | $278.1M | $220.0M | $182.9M | $161.5M | $127.7M |
| Operating Income | $-535.0M | $-536.0M | $-569.0M | $-648.9M | $-381.7M | $-330.1M | $-424.2M | $-371.4M |
| Operating Margin | -79.5% | -95.7% | -131.0% | -178.6% | -108.6% | -121.8% | -409.0% | -406.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-571.0M | $-567.0M | $-609.0M | $-701.7M | $-453.0M | $-185.4M | $-399.4M | $-197.1M |
| Income Tax Expense | $4.0M | $2.0M | $-2.0M | $5.7M | $1.0M | $1.2M | $3.3M | $514.0K |
| Net Income | $-575.0M | $-569.0M | $-607.0M | $-707.4M | $-454.0M | $-186.6M | $-402.7M | $-197.6M |
| Net Margin | -85.4% | -101.6% | -139.8% | -194.7% | -129.2% | -68.8% | -388.3% | -216.0% |
| EPS (Basic) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | $-7.12 | $-3.97 |
| EPS (Diluted) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | $-7.12 | $-3.97 |
| Shares Outstanding (Basic) | 98.6M | 90.5M | 73.5M | 69.9M | 67.8M | 60.8M | 57.8M | 50.9M |
| Shares Outstanding (Diluted) | 98.6M | 90.5M | 73.5M | 69.9M | 67.8M | 60.8M | 57.8M | 50.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |